DE-120

DRUG2 trials

Sponsors

Santen Inc.

Conditions

Age-Related Macular Degeneration

Phase 1

A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration

CompletedNCT02022501

Santen Inc.Age-Related Macular Degeneration

Start: 2014-01-31End: 2016-04-21Updated: 2018-04-18

Phase 2

A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration

CompletedNCT02401945

Santen Inc.Age-Related Macular Degeneration

Start: 2015-04-30End: 2016-10-31Updated: 2018-04-18